

CURRICULUM VITAE

February 2019

Tatiana Baron

North Shore Diabetes & Endocrine Associates
3003 New Hyde Park Road
Suite 201
New Hyde Park, New York 11042
(516) 327-0850

Professional Experience

- 6/2017 – present **Partner, North Shore Diabetes and Endocrine Associates**
- 7/2012 to 6/2017 **North Shore Diabetes and Endocrine Associates**
- 7/2008 – 6/2009 **Chief Resident, Internal Medicine Residency Program**
Winthrop University Hospital, Mineola NY

Training

- 7/2009- **Endocrinology fellowship Program**
Winthrop University Hospital, Mineola, NY
- 7/2005 – 6/2008 **Internal Medicine Residency Program**
Winthrop University Hospital, Mineola, NY

Education

- 8/2000 – 5/2005 **D.O., New York college of Osteopathic Medicine**
Old Westbury, NY
- PSI SIGMA ALPHA HONOR SOCIETY
- 8/1997 – 1/2000 **B.A., New York University, College of Arts and Sciences**
New York, NY
- Biology Major
 - CUM LAUDE
 - Founders Day Award
- 9/1991 – 6/1995 **Medical Student, Moscow Medical Academy**
Moscow Russian Federation
- Honor Student

Licensure and Certifications

10/4/2011 **American Board of Internal Medicine Certification in
Endocrinology, Diabetes and Metabolism**
8/2009 **ACLS Certification**
10/2008 **New York State Medical License # 250931**
8/2008 **American Board of Internal Medicine certification**

Professional Memberships

9/2010 – Present **American Association of Clinical Endocrinologists**
3/2004 **PSI SIGMA ALPHA HONOR SOCIETY**
2/2011 - Present **Endocrine Society**

Presentations

4/2010 **Winthrop University Hospital House Staff Research Day**
Poster “Multiorgan effects of Pheochromocytoma”
3/2004 **Long Island Clinical Endocrinology Society Meeting**

Publications

Shapiro, Lawrence E, and Tatiana Baron. “The Efficacy of Thyroid Hormone Therapy in Brain-Dead Heart Donors: A Review of Thyroid Function in Health and Disease.” *The Brain Dead Organ Donor: Pathophysiology and Management*, Springer Science Business Media, 2013, pp. 91–105.

Research Experience

11/2010 - 2011 Sub-Investigatory: **EFC11319**: A randomized, double-blind, placebo-controlled, parallel group multicenter study to evaluate cardiovascular outcomes during treatment with Lixisenatide in type 2 diabetic patients after an acute coronary syndrome.
Winthrop University Hospital, Mineola, NY

10/2010 - 2011 Sub-Investigatory: **MKC-TI-162**: A phase 3b, Multicenter, Open-Label, Randomized, Forced-titration, Clinical Trial Evaluating the Efficacy and Safety of Technosphere Insulin Inhalation Powder, Using the Gen2 Inhaler, in combination with Insulin Glargine vs. Insulin Aspart in Combination with Insulin Glargine in Subject with Type 2 Diabetes Mellitus over a 16 week treatment Period.
Winthrop University Hospital Mineola, NY

10/2010 - 2011 Sub-Investigatory: **MKC-TI-164**: A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in s a subset of subjects with Type 1 or Type 2 Diabetes Enrolled in 1 of 3 Parent Trails.
Winthrop University Hospital, Mineola, NY

11/2010 - 2011 Sub- Investigator: **EAGLE**: A randomized, parallel-group, open-label, comparative study of insulin Glargine vs. liraglutide in insulin-naïve patients with type 2 diabetes treated with oral agents and not adequately controlled.
Winthrop University Hospital, Mineola, NY

9/2006 – 4/2010 Sub-Investigatory: **“Glycemic Variability Predicts Endothelial dysfunction” clinical trial**

10/2006 – 4/2007

Department of Endocrinology
Winthrop University Hospital Mineola, NY
Sub-Investigator: **“Vitamin D Supplementation for Cold and Flu
Prevention” clinical trial**
Bone Mineral Research Center
Winthrop University Hospital, Mineola, NY

Research Studies at North Shore Diabetes and Endocrine Associates

Sub Investigator- Insulin for Type 1 Diabetics- Mylan
Sub-Investigator – Oral Hypertriglyceridemia agent – KOWA
Sub Investigator- Injectable medication for Hyperlipidemia- Regeneron
Sub Investigator- MACE assessment of weight loss medication – Eisai
Sub Investigator-Injectable Diabetic Medication- Sanofi
Sub Investigator-Injectable Diabetic Medication-Sanofi
Sub Investigator- MACE assessment of an Oral Diabetic Agent- AstraZeneca
Sub Investigator-Diabetic Nephropathy-AbbVie
Sub Investigator-infusible medication for insulin pump- Halozyme Therapeutics
Sub Investigator-Oral Diabetic Agent- Bristol-Myers
Sub Investigator-Injectable medication for Hyperlipidemia- Amgen
Sub Investigator-Injectable Diabetic Medication- Sanofi
Sub Investigator-Insulin for Type 2 Diabetics- Sanofi
Sub Investigator-Insulin for Type 1 Diabetics- Sanofi
Sub Investigator-Insulin for Type 2 Diabetics- Lilly
Sub Investigator-Insulin for Type 1 Diabetics- Lilly
Sub Investigator- Diabetic Nephropathy-Abbott
Sub Investigator- Insulin Delivery Device- Valeritas
Sub Investigator- Oral Diabetic Agent- Johnson and Johnson
Sub Investigator- Oral Diabetic Agent- AstraZeneca